Lumipulse® G ProGRP (Pro-Gastrin-Releasing Peptide)
A marker of choice in lung cancer management
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of Pro-gastrin-releasing peptide [ProGRP (31-98)] in serum or plasma.
The ProGRP assay is intended to be used as an aid in differential diagnosis and for monitoring of patients with Small Cell Lung Cancer.
The assay utilises proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in up to 35 minutes.
Product number 297858
Product number 233160
Product number 233177
Click here to navigate
- Conditions of sale
- Related products
- Product inquiry
Advantages & Features
ProGRP (Pro-Gastrin-Releasing Peptide)
- is the recommended assay to distinguish SCLC (Small Cell Lung Cancer) from NSCLC (Non Small Cell Lung Cancer) because of their different treatments and prognoses
- is measurable in early stage SCLC and does not correlate with tumor extent (autocrine growth factor)
- when used as a single marker it is superior to any other tumor marker among the lung panel assays with regards to sensitivity for SCLC
- shows an significantly improved sensitivity in combination with NSE (Neuron Specific Enolase)
- is recommended by the NACB1 for post-operative surveillance, monitoring therapy in advanced disease, and detection of recurrent disease.
CLEIA - ChemiLuminescent Enzyme Immunoassay
- Broad dynamic assay range: 5-5000 pg/ml.
- LOD: 1,209 pg/ml.
- Precision (CV): Within run = 1,2-3,4% and total precision 3,4-4,6%.
- 25 minute reaction time.
- 30 days calibration stability.
- Packaging: 42 tests per kit.
- Unique cartridge concept.
Test principle: Two-Step sandwich assay
The global burden of cancer continues to increase largely because of the aging and growth of the world population alongside an increasing adoption of cancer-causing behaviors, particularly smoking, in economically developing countries.
Lung cancer is the leading cancer site in males, comprising 17% of the total new cancer cases and 23% of the total cancer deaths2.
Did you know?
SCLC accounts for 20% of lung cancer patients, often has neuroendocrine components, and is primarily treated with chemotherapy and/or radiotherapy. SCLC is almost always caused by smoking.
ProGRP is expressed in neuroendocrine-derived tissues and tumors, including small cell lung cancer carcinoids, undifferentiated large cell carcinoma of the lung with neuroendocrine features, medullary thyroid carcinoma, and other neuroendocrine malignancies.
Serum levels of ProGRP have been shown to be elevated in a high proportion of patients diagnosed with SCLC while normal levels are found in patients with benign disease3.
- NACB: Practice Guidelines And Recommendations For Use Of Tumor Markers In The Clinic Lung Cancer (Section 3P)
- Globocan 2012 report.
- Fujirebio ProGRP package insert.
See the LUMIPULSE G1200 working in this video:
Conditions of sale
To read the end user conditions of sale for this product please visit our Resource center.
During this webinar Dr. Francesco Bonella (MD - Center for Interstitial & Rare Lung Disease, Department of Pulmonology, Ruhrlandklinik University...
Oct 19, 2020
Several fully automated and CLEIA-based LUMIPULSE G1200 systems from Fujirebio are right now performing fast, high sensitivity SARS CoV-2 antigen...
Aug 26, 2020
There are many reference centers across Europe that have included KL-6 as one of the biomarkers within the COVID-19 protocol to strengthen the battery...
Apr 30, 2020
How does the coronavirus disease Covid-19 impact Fujirebio's operations?
Please see the following statement on the impact of coronavirus disease Covid-19 on the operations of Fujirebio Europe (updated January 19, 2021).
Lung Marker Control
Product number 240-20 -
Lung Marker Control is intended for use as an assayed quality control serum to monitor the precision of laboratory testing procedures for the analysis of CYFRA and ProGRP with the LUMIPULSE G system.CE marked
Lumipulse® G CEA-N (Carcinoembryonic Antigen)
Product number 292662 -
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of carcinoembryonic antigen (CEA) in serum or plasma.CE marked
Lumipulse® G CYFRA (Cytokeratin Subunit 19 Fragment)
Product number 292945 -
Immunoreaction cartridges for in vitro diagnostic use with the LUMIPULSE G System for the quantitative measurement of cytokeratin subunit 19 fragment (CYFRA) in serum or plasma.CE marked
Lumipulse® G KL-6 (Krebs von den Lungen)
Product number 233207 -
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of sialylated carbohydrate antigen, KL-6 in serum or plasma.CE marked
Lumipulse® G Mesothelin
Product number 294192 -
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative determination Soluble Mesothelin Related Peptides (SMRP) in human serum or plasma.CE marked
Lumipulse® G PIVKA-II
Product number 233184 -
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of protein induced vitamin K absence or antagonist-II (PIVKA-II) in serum.CE marked
Lumipulse® G SCC (Squamous Cell Carcinoma)
Product number 298411, 235430 -
Immunoreaction cartridges for in vitro diagnostic use with the LUMIPULSE G instruments for the quantitative measurement of squamous cell carcinoma (SCC) antigen in human serum or plasma samples as an aid in the management of patients with squamous cell carcinoma.CE marked
Product number 703380 -
The LUMIPULSE G600II is the latest member of the Lumipulse G series of chemiluminescent enzyme immunoassay analyzers (CLEIA) from Fujirebio.CE marked
Product number 232002 -
A robust, mid-sized and fully automated chemiluminescent enzyme immunoassay (CLEIA) system from the already widely successful LUMIPULSE series.CE marked
CanAg® ProGRP EIA
Product number 220-10 -
The CanAg ProGRP EIA kit is an immunoassay for the quantitative determination of ProGRP in serum. The CanAg ProGRP assay is to be used as an aid in the differential diagnosis and in monitoring disease progression during the course of disease and treatment in small cell lung cancer patients. Testing for patient proGRP assay values should be used in conjunction with other clinical methods used in the management of patients with small cell lung cancer.CE marked